Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers.

Autor: Matuszczak M; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Kiljańczyk A; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Marciniak W; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland., Derkacz R; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland., Stempa K; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Baszuk P; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Bryśkiewicz M; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Sun P; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5G 1N8, Canada., Cheriyan A; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5G 1N8, Canada., Cybulski C; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland., Dębniak T; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Gronwald J; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland., Huzarski T; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland.; Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland., Lener MR; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Jakubowska A; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland., Szwiec M; Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland., Stawicka-Niełacna M; Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland., Godlewski D; OPEN, Kazimierza Wielkiego 24 St., 61-863 Poznań, Poland., Prusaczyk A; Medical and Diagnostic Center, 08-110 Siedlce, Poland., Jasiewicz A; Genetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego St., 36-200 Brzozów, Poland., Kluz T; Department of Gynecology, Gynecology Oncology and Obstetrics, Institute of Medical Sciences, Medical College, Rzeszow University, Rejtana 16c, 35-959 Rzeszow, Poland., Tomiczek-Szwiec J; Department of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland., Kilar-Kobierzycka E; Department of Oncology, District Specialist Hospital, Leśna 27-29 St., 58-100 Świdnica, Poland., Siołek M; Holycross Cancer Center, Artwińskiego 3 St., 25-734 Kielce, Poland., Wiśniowski R; Regional Oncology Hospital, Wyzwolenia 18 St., 43-300 Bielsko Biała, Poland., Posmyk R; Department of Clinical Genetics, Medical University of Bialystok, 15-089 Białystok, Poland., Jarkiewicz-Tretyn J; Non-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Toruń, Poland., Scott RJ; Medical Genetics, Hunter Medical Research Institute, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Pathology North, John Hunter Hospital, King and Auckland Streets, Newcastle, NSW 2300, Australia., Narod SA; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5G 1N8, Canada., Lubiński J; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland.
Jazyk: angličtina
Zdroj: Antioxidants (Basel, Switzerland) [Antioxidants (Basel)] 2024 May 16; Vol. 13 (5). Date of Electronic Publication: 2024 May 16.
DOI: 10.3390/antiox13050609
Abstrakt: BRCA1 mutations predispose women to breast and ovarian cancer. The anticancer effect of zinc is typically linked to its antioxidant abilities and protecting cells against oxidative stress. Zinc regulates key processes in cancer development, including DNA repair, gene expression, and apoptosis. We took a blood sample from 989 female BRCA1 mutation carriers who were initially unaffected by cancer and followed them for a mean of 7.5 years thereafter. There were 172 incident cases of cancer, including 121 cases of breast cancer, 29 cases of ovarian cancers, and 22 cancers at other sites. A zinc level in the lowest tertile was associated with a modestly higher risk of ovarian cancer compared to women with zinc levels in the upper two tertiles (HR = 1.65; 95% CI 0.80 to 3.44; p = 0.18), but this was not significant. Among those women with zinc levels in the lowest tertile, the 10-year cumulative risk of ovarian cancer was 6.1%. Among those in the top two tertiles of zinc level, the ten-year cumulative risk of ovarian cancer was 4.7%. There was no significant association between zinc level and breast cancer risk. Our preliminary study does not support an association between serum zinc level and cancer risk in BRCA1 mutation carriers.
Databáze: MEDLINE